• Explore /
  • Poster
  • / Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database.

Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database.

Abstract Poster

Authors

Shuichi Hironaka

Shuichi Hironaka

Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu, Japan

Shuichi Hironaka , Yoshito Komatsu , Yoshinori Tanizawa , Zhihong Cai , Yongzhe Piao , Narikazu Boku

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 177)

DOI

10.1200/JCO.2021.39.3_suppl.177

Abstract #

177

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Timothy Jay Price

First Author: Mayur Amonkar

First Author: Zhi Peng

First Author: Yelena Y. Janjigian